Sanofi Rips Fed. Circ. Rehearing Bid In Repatha IP Fight
Sanofi is defending a controversial Federal Circuit ruling that axed two Amgen patents covering the cholesterol medication Repatha, arguing that Amgen's claims that the full court should review the ruling because...To view the full article, register now.
Already a subscriber? Click here to view full article